TY - JOUR
T1 - Influence of norfloxacin on blood coagulation in children
AU - Sunakawa, Keisuke
AU - Yokota, Takao
AU - Akita, Hironobu
AU - Iwata, Satoshi
AU - Sato, Yoshitake
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1990
Y1 - 1990
N2 - There have been reports of hemorrhagic manifestations associated with the administration of antibiotics, mainly beta-lactams recently introduced into the market. During the course of a clinical study to assess the safety of a new quinolone, norfloxacin (NFLX) in children, we investigated the drug's influence on blood coagulation and platelet functions. ADP-induced platelet aggregation was measured in seven pediatric patients from 6 months ‘to 10 years’ old being treated with NFLX. The mean values were 51.0±13.1% before administration and 63.8±17.2% during the treatment, showing an improvement in platelet function differing from cases commonly treated with other oral antibacterials. In parallel, tests on blood coagulation and PIVKA II were performed, and no abnormalities caused by NFLX were observed. Our results suggest that NFLX in children has less adverse effect on the normal function of hemostasis and blood coagulation.
AB - There have been reports of hemorrhagic manifestations associated with the administration of antibiotics, mainly beta-lactams recently introduced into the market. During the course of a clinical study to assess the safety of a new quinolone, norfloxacin (NFLX) in children, we investigated the drug's influence on blood coagulation and platelet functions. ADP-induced platelet aggregation was measured in seven pediatric patients from 6 months ‘to 10 years’ old being treated with NFLX. The mean values were 51.0±13.1% before administration and 63.8±17.2% during the treatment, showing an improvement in platelet function differing from cases commonly treated with other oral antibacterials. In parallel, tests on blood coagulation and PIVKA II were performed, and no abnormalities caused by NFLX were observed. Our results suggest that NFLX in children has less adverse effect on the normal function of hemostasis and blood coagulation.
KW - Norfloxacin
UR - http://www.scopus.com/inward/record.url?scp=0025272981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025272981&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.38.26
DO - 10.11250/chemotherapy1953.38.26
M3 - Article
AN - SCOPUS:0025272981
VL - 38
SP - 26
EP - 30
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
SN - 0009-3165
IS - 1
ER -